Cancer Immunology Research Table of...
3
WHAT WE'RE READING 501 Literature Highlights: Impactful Papers Published Elsewhere CANCER IMMUNOLOGY AT THE CROSSROADS 502 Hallmarks of T-cell Exit from Quiescence Nicole M. Chapman and Hongbo Chi PRIORITY BRIEF 509 Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases Michael S. Magee, Tara S. Abraham, Trevor R. Baybutt, John C. Flickinger Jr, Natalie A. Ridge, Glen P. Marszalowicz, Priyanka Prajapati, Adam R. Hersperger, Scott A. Waldman, and Adam E. Snook CAR-T cells targeting GUCY2C were generated that eradicated GUCY2C-expressing human colorectal cancer xenografts in mice. This therapy has the potential to be translated to human studies investigating CAR-T targets for colorectal cancer immunotherapy. RESEARCH ARTICLES 517 CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells Jens H.W. Pahl, Joachim Koch, Jana-Julia G€ otz, Annette Arnold, Uwe Reusch, Thorsten Gantke, Erich Rajkovic, Martin Treder, and Adelheid Cerwenka Pre-activation via CD16A, a potent cytotoxicity receptor engaged by therapeutic bispecific antibodies, promoted NK cell proliferation and expansion. These CD16A-experienced NK cells exerted memory-like enhanced cytotoxicity and IFNg production upon restimulation with tumor cells. 528 Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness Malin E. Winerdal, David Krantz, Ciputra A. Hartana, Ali A. Zirakzadeh, Ludvig Linton, Emma A. Bergman, Robert Rosenblatt, Janos Vasko, Farhood Alamdari, Johan Hansson, Benny Holmstr€ om, Markus Johansson, Max Winerdal, Per Marits, Amir Sherif, and Ola Winqvist Tregs localized to the invasive front of human bladder tumors inhibited the expression of MMP2, an enzyme that cleaves extracellular matrix and promotes metastasis. Therefore, caution should be exercised in the clinical targeting of Tregs in inflammation-driven cancers. 539 AMD3100 Augments the Efficacy of Mesothelin- Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression Binghao Li, Yang Zeng, Patrick M. Reeves, Chongzhao Ran, Qiuyan Liu, Xiying Qu, Yingying Liang, Zhao Liu, Jianping Yuan, Pierre R. Leblanc, Zhaoming Ye, Ann E. Sluder, Jeffrey A. Gelfand, Timothy A. Brauns, Huabiao Chen, and Mark C. Poznansky CXCR4 antagonist AMD3100 promoted conversion of Tregs to helper-like cells and reduced PD-1 expression on CD8 þ T cells in mesothelioma. The combination of AMD31000 with a mesothelin-targeting immune stimulator, VIC-008, controlled tumors and prolonged survival of tumor-bearing animals. 552 Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer Elena Jachetti, Valeria Cancila, Alice Rigoni, Lucia Bongiovanni, Barbara Cappetti, Beatrice Belmonte, Claudia Enriquez, Patrizia Casalini, Paola Ostano, Barbara Frossi, Sabina Sangaletti, Claudia Chiodoni, Giovanna Chiorino, Carlo E. Pucillo, Claudio Tripodo, and Mario P. Colombo In a mouse model of prostate cancer, the incidence of adenocarcinoma was reduced when mast cells were lacking, correlating with a regained ability to mount a tumor-specific T-cell response. Mast cell inhibition required CD40L-CD40 interaction with myeloid suppressors. 566 Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation Qi Zeng, Juan Fu, Michael Korrer, Mikhail Gorbounov, Peter J. Murray, Drew Pardoll, David L. Masica, and Young J. Kim MDSCs from HNSCC patients exhibited upregulated caspase-1, a member of the inflammasome complex, and directly promoted tumor cell proliferation. Silencing caspase-1 activity in a mouse model reduced tumor growth, suggesting that targeting caspase-1 could have therapeutic potential. 578 Protumor Steering of Cancer Inflammation by p50 NF-kB Enhances Colorectal Cancer Progression Chiara Porta, Alessandro Ippolito, Francesca Maria Consonni, Lorenzo Carraro, Giuseppe Celesti, Carmen Correale, Fabio Grizzi, Fabio Pasqualini, Silvia Tartari, Maurizio Rinaldi, Paolo Bianchi, Fiorella Balzac, Stefania Vetrano, Emilia Turco, Emilio Hirsch, Luigi Laghi, and Antonio Sica The p50 NF-kB subunit was identified as a key driver of the tumor-promoting reprogramming of TAMs, which could modulate the tumor microenvironment in colorectal cancer, demonstrating its potential as a candidate for prognostic and targeted therapeutic intervention. May 2018 Volume 6 Issue 5 Cancer Immunology Research Table of Contents iii on February 15, 2019. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from
-
Upload
nguyenmien -
Category
Documents
-
view
213 -
download
0
Transcript of Cancer Immunology Research Table of...
WHAT WE'RE READING
501 Literature Highlights: Impactful Papers PublishedElsewhere
CANCER IMMUNOLOGYAT THECROSSROADS
502 Hallmarks of T-cell Exit from QuiescenceNicole M. Chapman and Hongbo Chi
PRIORITY BRIEF
509 Human GUCY2C-Targeted Chimeric AntigenReceptor (CAR)-Expressing T Cells EliminateColorectal Cancer MetastasesMichael S. Magee, Tara S. Abraham, Trevor R. Baybutt,John C. Flickinger Jr, Natalie A. Ridge, Glen P. Marszalowicz,Priyanka Prajapati, Adam R. Hersperger, Scott A. Waldman,and Adam E. SnookCAR-T cells targeting GUCY2C were generated that eradicatedGUCY2C-expressing human colorectal cancer xenografts in mice.This therapy has the potential to be translated to human studiesinvestigating CAR-T targets for colorectal cancer immunotherapy.
RESEARCH ARTICLES
517 CD16A Activation of NK Cells Promotes NK CellProliferation and Memory-Like Cytotoxicityagainst Cancer CellsJens H.W. Pahl, Joachim Koch, Jana-Julia G€otz,Annette Arnold, Uwe Reusch, Thorsten Gantke,Erich Rajkovic, Martin Treder, and Adelheid CerwenkaPre-activation via CD16A, a potent cytotoxicity receptor engagedby therapeutic bispecific antibodies, promoted NK cellproliferation and expansion. These CD16A-experienced NK cellsexerted memory-like enhanced cytotoxicity and IFNg productionupon restimulation with tumor cells.
528 Urinary Bladder Cancer Tregs Suppress MMP2 andPotentially Regulate InvasivenessMalin E. Winerdal, David Krantz, Ciputra A. Hartana,Ali A. Zirakzadeh, Ludvig Linton, Emma A. Bergman,Robert Rosenblatt, Janos Vasko, Farhood Alamdari,Johan Hansson, Benny Holmstr€om, Markus Johansson,Max Winerdal, Per Marits, Amir Sherif, and Ola WinqvistTregs localized to the invasive front of human bladder tumorsinhibited the expression of MMP2, an enzyme that cleavesextracellular matrix and promotes metastasis. Therefore, cautionshould be exercised in the clinical targeting of Tregs ininflammation-driven cancers.
539 AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 inMesothelioma by Modulating IntratumoralImmunosuppressionBinghao Li, Yang Zeng, Patrick M. Reeves, Chongzhao Ran,Qiuyan Liu, Xiying Qu, Yingying Liang, Zhao Liu,Jianping Yuan, Pierre R. Leblanc, Zhaoming Ye,Ann E. Sluder, Jeffrey A. Gelfand, Timothy A. Brauns,Huabiao Chen, and Mark C. PoznanskyCXCR4 antagonist AMD3100 promoted conversion of Tregs tohelper-like cells and reduced PD-1 expression on CD8þ T cells inmesothelioma. The combination of AMD31000 with amesothelin-targeting immune stimulator, VIC-008, controlledtumors and prolonged survival of tumor-bearing animals.
552 Cross-Talk between Myeloid-Derived SuppressorCells and Mast Cells Mediates Tumor-SpecificImmunosuppression in Prostate CancerElena Jachetti, Valeria Cancila, Alice Rigoni,Lucia Bongiovanni, Barbara Cappetti, Beatrice Belmonte,Claudia Enriquez, Patrizia Casalini, Paola Ostano,Barbara Frossi, Sabina Sangaletti, Claudia Chiodoni,Giovanna Chiorino, Carlo E. Pucillo, Claudio Tripodo, andMario P. ColomboIn a mouse model of prostate cancer, the incidence ofadenocarcinoma was reduced when mast cells were lacking,correlating with a regained ability to mount a tumor-specific T-cellresponse. Mast cell inhibition required CD40L-CD40 interactionwith myeloid suppressors.
566 Caspase-1 from Human Myeloid-DerivedSuppressor Cells Can PromoteT Cell–Independent Tumor ProliferationQi Zeng, Juan Fu, Michael Korrer, Mikhail Gorbounov,Peter J. Murray, Drew Pardoll, David L. Masica, andYoung J. KimMDSCs fromHNSCC patients exhibited upregulated caspase-1, amember of the inflammasome complex, and directly promotedtumor cell proliferation. Silencing caspase-1 activity in a mousemodel reduced tumor growth, suggesting that targeting caspase-1could have therapeutic potential.
578 Protumor Steering of Cancer Inflammation by p50NF-kB Enhances Colorectal Cancer ProgressionChiara Porta, Alessandro Ippolito,Francesca Maria Consonni, Lorenzo Carraro,Giuseppe Celesti, Carmen Correale, Fabio Grizzi,Fabio Pasqualini, Silvia Tartari, Maurizio Rinaldi,Paolo Bianchi, Fiorella Balzac, Stefania Vetrano,Emilia Turco, Emilio Hirsch, Luigi Laghi, and Antonio SicaThe p50 NF-kB subunit was identified as a key driver of thetumor-promoting reprogramming of TAMs, which could modulatethe tumor microenvironment in colorectal cancer, demonstratingits potential as a candidate for prognostic and targeted therapeuticintervention.
May 2018 � Volume 6 � Issue 5
Cancer Immunology Research
Table ofContents
iii
on February 15, 2019. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from
594 Rapid Construction of Antitumor T-cell ReceptorVectors from Frozen Tumors for EngineeredT-cell TherapyTakemasa Tsuji, Akira Yoneda, Junko Matsuzaki,Anthony Miliotto, Courtney Ryan, Richard C. Koya, andKunle OdunsiTumor-specific TCRa and b chain pairs were efficiently identifiedfrom a retroviral library of randomly paired TCRs recoveredfrom frozen tumor biopsies and selected by tetramers. TherapeuticT cells expressing these TCRs had potent antitumor activity.
605 Improving CART-Cell Therapy of Solid Tumorswith Oncolytic Virus–Driven Production of aBispecific T-cell EngagerAnna Wing, Carlos Alberto Fajardo, Avery D. Posey Jr,Carolyn Shaw, Tong Da, Regina M. Young,Ramon Alemany, Carl H. June, and Sonia GuedanThe efficacy of chimeric antigen receptor T-cell therapy wasimproved by oncolytic-adenovirus delivery of a bispecific T-cellengager to the tumor microenvironment. T-cell activation wasincreased and tumor resistance overcome as a result of its dualantigen specificity.
617 Sustained Persistence of IL2 Signaling Enhancesthe Antitumor Effect of Peptide Vaccinesthrough T-cell Expansion and Preventing PD-1InhibitionHussein Sultan, Takumi Kumai, Valentyna I. Fesenkova,Aaron E. Fan, Juan Wu, Hyun-II Cho, Hiroya Kobayashi,Yasuaki Harabuchi, and Esteban CelisIL2 signaling improves potency of peptide vaccines but at thecost of toxicity. Improving persistence of IL2 avoids toxicity andpromotes antitumor T cells by enhancing their expansion andpreventing PD-1 inhibition.
AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
ABOUT THE COVER
Regulatory T cells contribute to theprotumor environment in cancer. Largenumbers in tumors, or a high regulatoryT:CD8þ T cell ratio, is associated with a poorprognosis. However, that relationship is notalways found in urinary bladder cancer.Winerdal et al. first established that theregulatory T cells in human bladder cancersare functionally suppressive like otherregulatory T cells. They then observed thatthese regulatory T cells suppressed tumorand macrophage production of MMP2, ametalloproteinase that aids metastasis.Thus, higher numbers of regulatory T cellscongregating at the invasive front of a tumorcorrelated with survival. Read more in thisissue on page 528. Original micrographfrom the Winqvist laboratory shows abladder tumor infiltrated and surroundedby brown T cells, some of which areregulatory. Artwork by Lewis Long.
iv
Table of Contents
on February 15, 2019. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from
2018;6:501-627. Cancer Immunol Res 6 (5)
Updated version
http://cancerimmunolres.aacrjournals.org/content/6/5
Access the most recent version of this article at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerimmunolres.aacrjournals.org/content/6/5To request permission to re-use all or part of this article, use this link
on February 15, 2019. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from
